Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

02/03/2015
Inflammation persists despite very early HIV treatment

Biomarkers of inflammation increase during acute HIV infection and remain elevated despite early suppressive antiretroviral therapy, according to a study presented at CROI 2015, in Seattle, Washington. The study, presented by Netanya Sandler Utay, M.D., followed 78 acutely HIV-infected individuals and 109 HIV-negative individuals from Thailand, from diagnosis or enrollment to 96...

Read more...

Source Source: TheBodyPRO.com





02/03/2015
Impact of specific antiretroviral drugs on non-AIDS mortality

LPV, ATV, NVP, but not EFV, tied to higher non-AIDS death rate in D:A:D Analysis of the D:A:D cohort linked cumulative use of lopinavir, atazanavir, or nevirapine to small but significant increases in the non-AIDS death rate [1]. The same analysis tied recent efavirenz exposure to about a 15% lower non-AIDS death rate. D:A:D is the large ongoing study of...

Read more...

Source Source: NATAP





02/03/2015
Natco Pharma ties up with Gilead on hepatitis C drugs

Natco Pharma Ltd said on Monday it has agreed a deal with Gilead Sciences Inc to supply generic copies of the U.S. drugmaker's chronic hepatitis C medicines, including $1,000-a-pill drug Sovaldi, in 91 developing nations. Natco, a mid-sized player in India's crowded pharmaceutical industry, is the latest generic drugmaker to team up with Gilead on Sovaldi, having...

Read more...

Source Source: REUTERS





02/03/2015
Dynavax announces second independent DSMB recommendation to continue Phase 3 study of HEPLISAV-B(TM)

BERKELEY, CA -- 02/03/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine, has completed its second prespecified review and has recommended that the study continue...

Read more...





02/03/2015
Roche launches next-generation viral load assay for HBV in markets accepting the CE mark

cobas HBV assay offers unparalleled performance on the cobas 6800/8800 Systems Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today (March 2) the commercial availability of the cobas® HBV quantitative nucleic acid test for use on the cobas® 6800/8800 Systems—adding to the viral load monitoring portfolio on the newest molecular diagnostic platforms from Roche. The new...

Read more...

Source Source: Roche